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 The very high incidence of oesophageal squamous cell carcinoma (ESCC) in Golestan Province in northeastern Iran was suggested by 
 
 studies in the 1970s as partly due to opium use, which is not uncommon in this area, but based on limited numbers. From December 
 
 2003 to June 2007, we administered a validated structured questionnaire to 300 ESCC cases and 571 controls, matched on 
 
 neighbourhood of residence, age (±2 years), and sex. We used conditional logistic regression models to calculate odds ratios (ORs) 
 
 and 95% confidence intervals (95% CIs) adjusted for potential confounders. Compared with those who used neither tobacco nor 
 
 opium, risk of ESCC was increased in those who used tobacco only (OR, 95% CI: 1.70, 1.05–2.73), in those who used opium only  
 (2.12, 1.21–3.74), and in those who used both tobacco and opium (2.35, 1.50–3.67). All forms of tobacco use (cigarettes, hookah,  
 and nass) were associated with higher ESCC risk. Similarly, use of both crude opium and other forms of opium were associated with  
 higher risk. Alcohol consumption was seen in only 2% of the cases and 2% of the controls, and was not associated with ESCC risk.  
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Incidence and mortality rates of oesophageal squamous cell 
carcinoma (ESCC) in the eastern part of Golestan Province, 
northeast Iran, are among the highest in the world (Mahboubi 
et al, 1973; Kamangar et al, 2007). Studies conducted by the 
International Agency for Research on Cancer (IARC) and Institute 
of Public Health Research (IPHR) of the University of Tehran in 
the 1970s suggested that opium consumption was one causal factor 
(Cook-Mozaffari et al, 1979). Two studies found an almost six-fold 
higher prevalence of appreciable levels (X1 mg ml-1) of urinary 
morphine among residents of the high-risk areas than in lower risk 
areas (Joint Iran –IARC Study Group, 1977; Ghadirian et al, 1985). 
One of these studies prematurely terminated in 1979, found a two­
fold increased positivity rate for urinary opium metabolites among 
spouses of 41 case subjects compared with matched controls 
(Ghadirian et al, 1985). Opium use is still prevalent in Golestan 
Province, especially among rural men (Pourshams et al, 2004), and 
may contribute to the high rates of ESCC in this area. 
Heavy alcohol consumption and cigarette smoking are major 
causes of ESCC in most parts of the world (Tuyns, 1983; Brown 
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et al, 1994, 2001), whereas in the 1970s alcohol consumption was 
rare in Golestan Province, especially among rural people (Cook-
Mozaffari et al, 1979). These same studies showed that cigarette 
smoking, although associated with a two-fold increased risk of 
ESCC in Golestan (Cook-Mozaffari et al, 1979), was lower than in 
Western countries, where it increases risk by 3 – 5-fold. Golestan 
people may smoke tobacco using a hookah (water pipe) or chew 
tobacco as nass, a combination of tobacco, ash, and lime (Joint 
Iran– IARC Study Group, 1977; Cook-Mozaffari et al, 1979; 
Pourshams et al, 2004), but these have been little studied in 
relation to ESCC. 
In 2003, we initiated a new case –control study to assess the role 
of various risk factors in ESCC in Golestan Province. 
MATERIALS AND METHODS 
Case and control selection 
The study area included the counties of Gonbad, Minoodasht, 
Kalaleh, Azadshahr, and Ramian in eastern Golestan province. 
Approximately half of the residents of the study area are of 
Turkmen ethnicity, and the rest Persians, Kurds, Turks, and 
others. Cases were recruited at Atrak Clinic in Gonbad City, the 
largest in eastern Golestan Province, and is the only specialised 
clinic covering ESCC. Local physicians were asked to refer any 
suspected upper gastrointestinal tract cancers to Atrak Clinic. A 
local cancer registry showed that approximately 70% of the 
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incident oesophageal cancer cases during the study period were 
referred to Atrak Clinic (unpublished). 
Case subjects were recruited from December 2003 to June 2007, 
had histopathologically confirmed ESCC, and agreed to participate 
in the study. Other eligibility criteria were being at least 18 years of 
age, residing in the study area at the time of registration, and 
having no history of concurrent cancer in other organs or history 
of previous cancer in any organ. All the patients underwent 
oesophago-gastro-duodenal videoendoscopy at Atrak Clinic, and 
biopsy samples were sent to the Tehran University Digestive 
Disease Research Center (DDRC), in Tehran, where they were 
examined by experienced pathologists. 
For each case subject, we attempted to select two population-
based control subjects matched to the case for neighbourhood 
of residence or village, age (±2 years), and sex. However, for a 
minority of cases (B10%), we found only one matched control. In 
both rural villages and urban areas, the family health census, which 
is conducted annually by the Iranian Public Health Network, was 
used to identify eligible controls. In each village, our interview 
group identified all of the potentially eligible controls and 
randomly selected one to interview. If the first person could not 
be interviewed for any reason, the second person on the list was 
invited, and so forth. In urban areas, a list of the eligible controls 
was ordered by geographic proximity to the case’s residence, with 
the list starting from the eligible person living closest to the case’s 
residence. If the first person was not available for interview, then 
the second closest person was invited, and so forth. 
Data collection 
The conduct of this study was reviewed and approved by the 
Institutional Review Boards of the DDRC, the US National Cancer 
Institute (NCI), and IARC. After obtaining written informed 
consent from each subject, two trained interviewers, a nurse and a 
physician, administered a structured general questionnaire. Also, a 
nutritionist administered a validated semiquantitative food 
frequency questionnaire that was specifically developed for this 
area (Malekshah et al, 2006). During the pilot phase, which 
extended from March 2002 to November 2003 (Islami et al, 2004), 
interviewers were given a thorough training, questionnaires were 
tested for reliability and validity, and databases and other facilities 
were improved. To diminish interindividual variation, a limited 
number of staff conducted the face-to-face interviews and no 
proxies were used. Case subjects were interviewed on the day of 
diagnostic upper gastrointestinal endoscopy at the Atrak Clinic. 
Rural controls were interviewed in village health houses, urban 
controls in urban health centres except those selected from 
Gonbad City, who were interviewed at a research facility 
established by DDRC for an ongoing cohort study on upper 
gastrointestinal tract cancers (Pourshams et al, 2004). 
The questionnaire covered lifelong history of tobacco use, 
including smoking cigarettes, using hookah (water pipe), and 
chewing nass, with starting and stopping ages and daily amount 
used. Also, any change in amount and type of tobacco use was 
recorded. Ever-cigarette smokers, ever-hookah users, and ever­
nass users were those who had smoked, used, or chewed cigarettes, 
hookah, or nass (respectively) at least weekly for a period of 6 
months or more. Ever-tobacco users were individuals who had 
done any of the above, further classified as current and former 
users. Current users were those who had practised any of these 
habits within 1 year before the interview. Former users were those 
who had stopped their habit at least 1 year prior to the interview. 
The general questionnaire covered opium use, which in Golestan 
includes teriak (crude opium), shireh (a refined opium extract) 
(Hewer et al, 1978), sukhteh (opium dross left in pipes after 
smoking opium), and heroin. Teriak and shireh can be smoked or 
ingested, sukhteh is usually ingested, and heroin is usually 
injected. Opium users, defined as subjects who had consumed 
opium at least once per week for a minimum of 6 months, were 
asked about type(s) of opiate used, the route of administration, the 
age they started and stopped, and the amount consumed. Study 
participants were also asked whether they had been given opiates 
during infancy or childhood. 
Alcohol consumption in the study area is uncommon (Pourshams 
et al, 2004). Subjects were asked about type of alcohol used (beer, 
imported spirit, country spirit, and others), starting and stopping 
ages, and the amount and frequency of use. 
Detailed information was also collected on age, sex, education, 
ethnicity, place of residence, and other potential confounders. 
Responses to questions regarding opium, tobacco, and alcohol 
consumption in this area were previously validated (Abnet et al, 
2004; Pourshams et al, 2004). 
Statistical analysis 
For each exposure (opium, cigarette, hookah, nass, and alcohol), 
average intensity, total duration, and cumulative use (average 
intensity multiplied by duration of use) were categorised into three 
groups: no use, low use (pmedian use in controls), and high use 
(4median use). Age of first use was similarly categorised. 
Percentages were tabulated for each of these categories by case 
status. Conditional logistic regression models were used to 
calculate unadjusted and adjusted odds ratios (ORs) and 95% 
confidence intervals (95% CIs). In all analyses, nonusers were the 
referent group. By design, case and control subjects were matched 
for age, sex, and place of residence. Results were adjusted for 
education (as a marker of socioeconomic status) and ethnicity 
(Turkmen vs non-Turkmen). P-values for trend were obtained 
from adjusted models by assigning values of 0, 1, and 2 to no use, 
low use, and high use, respectively. 
We also analysed and present ORs (95% CIs) for different types 
of tobacco use and opium use, mutually adjusted for each other, 
and for education, ethnicity, and total intake of fruit and 
vegetables. Population attributable risks were obtained from these 
mutually adjusted models, using the prevalence of tobacco and 
opium use in the control subjects. Two-sided P-values p0.05 were 
Table 1 Demographic characteristics of ESCC cases and matched 
controls 
ESCC cases Matched controls 
N (%) N (%) 
Total 300 (100) 571 (100) 
Age (years) 
p50 
51 –60 
61 –70 
470 
32 (11) 
81 (27) 
86 (29) 
101 (34) 
61 (11) 
144 (25) 
177 (31) 
189 (33) 
Gender 
Male 
Female 
150 (50) 
150 (50) 
278 (49) 
293 (51) 
Place of residence 
Urban 
Rural 
82 (27) 
218 (73) 
150 (26) 
421 (74) 
Ethnicity 
Turkmen 
Non-Turkmen 
171 (57) 
129 (43) 
312 (55) 
259 (45) 
ESCC ¼ oesophageal squamous cell carcinoma. Although cases and controls were 
individually matched, the percentages of cases and controls are not necessarily equal 
in each age, gender, or place of residence category, because some cases have one 
matched control and others have two matched controls. 
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considered as statistically significant. All statistical analyses were 
done using Stata Software, version 10.0 (StataCorp., College 
Station, TX, USA). 
RESULTS 
Demographic characteristics of the study participants are sum­
marised in Table 1. A total of 300 ESCC case subjects were enrolled 
in this study. Of these, 271 had two matched controls and 29 had 
one in a total of 571. Mean age (s.d.) was 64.5 (10.1) for cases and 
64.3 (10.4) for controls. Of the cases, 50% were male, and 27% lived 
in urban areas. Matched for age, sex, and place of residence, 57% 
of cases and 55% of controls were of Turkmen ethnicity. 
In all, 90 cases (30%) and 106 controls (18%) had ever used 
opium (Table 2). Opium use was common in both men and in 
women; 32% of men (42% of cases and 27% of controls) and 13% 
of women (18% of cases and 11% of controls) had used opium. 
Prevalence of ever use increased with age, but was common in all 
age groups. Among controls, 11% of those aged p50 years, 19% of 
those 51 –70 years, and 21% of those 470 years had ever used 
opium. Ever use was associated with increased ESCC risk, with an 
adjusted OR (95% CI) of 2.00 (1.39 –2.88), and for use earlier than 
a year prior to diagnosis, was 1.92 (1.30 –2.84). Average intensity 
of use, duration of use, cumulative use, and age at first use all 
Table 2 Opium use in ESCC cases and matched controls 
ESCC cases 
N (%) 
Matched controls 
N (%) 
Unadjusted 
OR (95% CI) 
Adjusted 
OR (95% CI)a P for trendb 
Opium use 
Never 
Ever 
210 (70) 
90 (30) 
465 (81) 
106 (18) 
Referent 
1.95 (1.36 –2.78) 
Referent 
2.00 (1.39 –2.88) 
— 
Average intensity 
Never used 
p median (1.5 units per day)c,d 
4 median 
210 (70) 
42 (14) 
48 (16) 
465 (81) 
53 (9) 
53 (9) 
Referent 
1.75 (1.11 –2.75) 
2.19 (1.37 –3.51) 
Referent 
1.72 (1.08 –2.72) 
2.38 (1.47 –3.85) 
o0.001 
Duration 
Never used 
p median (8.5 years)d 
4 median 
210 (70) 
34 (11) 
56 (19) 
465 (81) 
53 (9) 
53 (9) 
Referent 
1.44 (0.88 –2.39) 
2.37 (1.54 –3.65) 
Referent 
1.47 (0.89 –2.44) 
2.47 (1.59 –3.84) 
o0.001 
Cumulative usee 
Never used 
p median (15.5 unit-years)c,d 
4 median 
210 (70) 
41 (14) 
49 (16) 
465 (81) 
53 (9) 
53 (9) 
Referent 
1.74 (1.10 –2.75) 
2.19 (1.38 –3.47) 
Referent 
1.73 (1.09 –2.74) 
2.34 (1.45 –3.78) 
o0.001 
Age started 
Never used 
4 median 
p median (50 years)d 
210 (70) 
29 (10) 
61 (20) 
465 (81) 
50 (9) 
56 (10) 
Referent 
1.26 (0.74 –2.16) 
2.50 (1.63 –3.84) 
Referent 
1.26 (0.74 –2.16) 
2.64 (1.71 –4.09) 
o0.001 
Type of opium used 
Never used 
Crude opium (teriak) only 
Refined opium (shireh) only 
Both 
210 (70) 
66 (22) 
14 (5) 
10 (3) 
465 (81) 
95 (17) 
8 (1) 
3 (1) 
Referent 
1.56 (1.06 –2.31) 
3.84 (1.57 –9.42) 
7.36 (1.99 –27.2) 
Referent 
1.62 (1.09–2.40) 
3.41 (1.35 –8.60) 
8.80 (2.28 –33.9) 
— 
Route of administration 
Never used 
Smoked only 
Ingested only 
Both 
210 (70) 
45 (15) 
30 (10) 
15 (5) 
465 (81) 
62 (11) 
38 (7) 
6 (1) 
Referent 
1.67 (1.06 –2.59) 
1.86 (1.07 –3.21) 
5.41 (2.05 –14.2) 
Referent 
1.67 (1.06 –2.63) 
1.90 (1.09 –3.32) 
6.61 (2.42 –18.0) 
— 
95% CI ¼ 95% confidence interval; ESCC ¼ oesophageal squamous cell carcinoma; OR ¼ odds ratio. ORs were obtained from conditional logistic regression models. aAdjusted 
for education and ethnicity. bP for trend was obtained from conditional logistic regression models by assigning values of 0, 1, and 2 to no use, below median, and above median 
use, respectively. cEach unit is one ‘nokhod’, which is approximately equal to 0.2 g. dWe used the median in control subjects as the dividing cut point. eCumulative use was 
calculated by multiplying intensity of use (per day) by duration of use (in years). 
1859 
showed significant dose – response associations with ESCC risk (all 
P-values for trend o0.001). No subject was a sukhteh or heroin 
user. Using the teriak or shireh form of opium was associated with 
higher risk of ESCC; adjusted ORs (95% CIs) for teriak use only, 
shireh use only, or use of both were 1.62 (1.09 –2.40), 3.41 (1.35 – 
8.60), and 8.80 (2.28 – 33.9), respectively. Both routes of adminis­
tration also increased risk of ESCC; adjusted ORs (95% CIs) for 
smoking only, ingestion only, and both were 1.67 (1.06 – 2.63), 1.90 
(1.09–3.32), and 6.61 (2.42 –18.0), respectively. Of the 250 cases 
and 509 controls who knew whether they were given opium in their 
childhood, 23 cases (9%) and 37 controls (7%) stated that they had 
received opiates during that time; the adjusted OR (95% CI) was 
1.11 (0.61 –2.03). 
A total of 67 cases (22%) and 99 controls (17%) ever regularly 
smoked cigarettes, and this habit was associated with a nearly 
significant increased ESCC risk, adjusted OR (95% CI) being 1.47 
(0.98–2.21). Risk was higher in current than in former smokers, in 
those who smoked above the median intensity among smoking 
controls (11 cigarettes per day), for longer than the median 
duration among smoking controls (21 years), in those whose 
cumulative pack-years was higher than median among smoking 
controls (13.5 pack-years), and in those who started smoking 
earlier than the median age of starting among controls (25 years); 
P-values for trend were significant for all of these comparisons 
(Table 3). 
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Table 3 Tobacco use in ESCC cases and matched controls 
ESCC cases Matched controls Unadjusted Adjusted 
N (%) N (%) OR (95% CI) OR (95% CI)a P for trendb 
Cigarette smokingc 
Never 232 (78) 471 (83) Referent Referent — 
Ever 67 (22) 99 (17) 1.35 (0.92–2.00) 1.47 (0.98–2.21) 
Cigarette smoking 
Never used 232 (78) 471 (83) Referent Referent 0.05
 
Former smoker 34 (11) 56 (10) 1.24 (0.75–2.03) 1.34 (0.80–2.23)
 
Current smoker 33 (11) 43 (8) 1.49 (0.90–2.48) 1.63 (0.97–2.76)
 
Average intensity 
Never used 232 (78) 471 (83) Referent Referent 0.01
 
p median (11 cigarettes per day)d 22 (7) 49 (9) 0.89 (0.51–1.56) 0.98 (0.55–1.75)
 
4 median 45 (15) 50 (9) 1.84 (1.13–2.99) 1.98 (1.20–3.25)
 
Duration 
Never used 232 (78) 471 (83) Referent Referent 0.04
 
p median (21 years)d 30 (10) 50 (9) 1.18 (0.72–1.94) 1.27 (0.76–2.11)
 
4 median 37 (12) 49 (9) 1.58 (0.95–2.62) 1.73 (1.03–2.93)
 
Cumulative usee 
Never used 232 (78) 471 (83) Referent Referent 0.05 
p median (13.5 pack-years)d 31 (10) 50 (9) 1.22 (0.74–2.01) 1.36 (0.81–2.27) 
4 median 36 (12) 49 (9) 1.52 (0.91–2.53) 1.61 (0.95–2.74) 
Age started 
Never used 232 (78) 471 (83) Referent Referent 0.02
 
4 median 23 (8) 46 (8) 0.98 (0.57–1.68) 1.07 (0.62–1.86)
 
p median (25 years)d 44 (15) 53 (9) 1.75 (1.08–2.84) 1.90 (1.15–3.11)
 
Hookah smoking 
Never 280 (93) 548 (96) Referent Referent — 
Ever 20 (7) 23 (4) 1.81 (0.95–3.43) 1.85 (0.95–3.58) 
Average intensity 
Never used 280 (93) 548 (96) Referent Referent 0.03
 
p median (3 times per day)d 11 (4) 18 (3) 1.29 (0.59–2.84) 1.31 (0.58–2.96)
 
4 median 9 (3) 5 (1) 3.51 (1.17–10.5) 3.57 (1.17–11.0)
 
Duration 
Never used 280 (93) 548 (96) Referent Referent 0.21
 
p median (19 years)d 15 (5) 12 (2) 2.52 (1.14–5.55) 2.45 (1.09–5.49)
 
4 median 5 (2) 11 (2) 1.00 (0.34–2.90) 1.11 (0.38–3.30)
 
Cumulative usee 
Never used 280 (93) 548 (96) Referent Referent 0.11
 
p median (32 hookah-years)d 12 (4) 12 (2) 2.07 (0.87–4.88) 2.04 (0.84–4.99)
 
4 median 8 (3) 11 (2) 1.55 (0.62–3.87) 1.66 (0.65–4.22)
 
Age started 
Never used 280 (93) 548 (96) Referent Referent 0.05
 
4 median 7 (2) 11 (2) 1.55 (0.62–3.87) 1.38 (0.51–3.69)
 
p median (40 years)d 13 (4) 12 (2) 2.22 (0.99–5.00) 2.31 (0.98–5.48)
 
Nass chewing 
Never 256 (85) 523 (92) Referent Referent — 
Ever 44 (15) 48 (8) 2.09 (1.28–3.42) 1.99 (1.21–3.28) 
Average intensity 
Never used 256 (85) 523 (92) Referent Referent 0.004
 
p median (5.5 times per day)d 17 (6) 24 (4) 1.59 (0.78–3.25) 1.50 (0.73–3.09)
 
4 median 27 (9) 24 (4) 2.52 (1.38–4.61) 2.42 (1.31–4.47)
 
Duration 
Never used 256 (85) 523 (92) Referent Referent 0.02
 
p median (26.5 years)d 26 (9) 24 (4) 2.44 (1.32–4.49) 2.24 (1.21–4.16)
 
4 median 18 (6) 24 (4) 1.69 (0.83–3.41) 1.69 (0.83–3.44)
 
Cumulative usee 
Never used 256 (85) 523 (92) Referent Referent 0.007
 
p median (150 nass-years)d 22 (7) 25 (4) 2.19 (1.08–3.73) 1.81 (0.97–3.40)
 
4 median 22 (7) 23 (4) 2.20 (1.15–4.21) 2.21 (1.15–4.27)
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Table 3 (Continued ) 
ESCC cases 
N (%) 
Matched controls 
N (%) 
Unadjusted 
OR (95% CI) 
Adjusted 
OR (95% CI)a P for trendb 
Age started 
Never used 
4 median 
p median (40 years)d 
256 (85) 
25 (8) 
19 (6) 
523 (92) 
27 (5) 
21 (4) 
Referent 
2.07 (1.06 –4.04) 
2.11 (1.13 –3.94) 
Referent 
1.91 (0.98 –3.75) 
2.06 (1.09 –3.89) 
0.01 
95% CI ¼ 95% confidence interval; ESCC ¼ oesophageal squamous cell carcinoma; OR ¼ odds ratio. ORs were obtained from conditional logistic regression models. bAdjusted 
for education and ethnicity. aP for trend was obtained from conditional logistic regression models by assigning values of 0, 1, and 2 to no use, below median, and above median 
use, respectively. cCigarette smoking status was unknown for one case and one control. Therefore, the total number of subjects in the cigarette smoking analysis is 299 cases and 
570 controls. dWe used the median in control subjects as the dividing cut point. eCumulative use was calculated by multiplying intensity of use (per day) by duration of use (in 
years). 
Table 4 The association between tobacco types and between tobacco and opium use, alone or in combination, and ESCC 
ESCC cases Matched controls Unadjusted Adjusted 
N (%) N (%) OR (95% CI) OR (95% CI)a 
Tobacco type used 
Never used 196 (66) 432 (76) Referent Referent 
Cigarettes only 41 (14) 68 (12) 1.32 (0.83–2.11) 1.50 (0.92 –2.43) 
Hookah only 12 (4) 18 (3) 1.66 (0.75–3.67) 1.69 (0.76 –3.77) 
Nass only 23 (8) 20 (4) 3.03 (1.53–5.96) 2.91 (1.46 –5.77) 
More than one type 27 (9) 32 (6) 2.12 (1.18–3.83) 2.11 (1.15 –3.86) 
Used neither tobacco nor opium 166 (56) 398 (70) Referent Referent 
Used tobacco but not opium 43 (14) 66 (12) 1.68 (1.05–2.68) 1.70 (1.05 –2.73) 
Used opium but not tobacco 30 (10) 34 (6) 2.22 (1.27–3.87) 2.12 (1.21 –3.74) 
Used both tobacco and opium 60 (20) 72 (13) 2.20 (1.42–3.40) 2.35 (1.50 –3.67) 
95% CI ¼ 95% confidence interval; ESCC ¼ oesophageal squamous cell carcinoma; OR ¼ odds ratio. ORs were obtained from conditional logistic regression models. aAdjusted 
for education, ethnicity, and total intake of fruit and vegetables. 
Of cases, 20 (7%) and 23 controls (4%) had ever used hookah 
(Table 3). Ever regularly smoking a hookah was associated with a 
nearly significant increased risk of ESCC, with an adjusted OR 
(95% CI) of 1.85 (0.95 – 3.58). Higher average intensity of use (P for 
trend ¼ 0.03) and younger age of starting (P for trend ¼ 0.05), but 
not duration of use (P for trend ¼ 0.21) or cumulative use (P for 
trend ¼ 0.11), showed significant associations with ESCC risk. Of 
cases, 44 (15%) and 48 controls (8%) had ever chewed nass. Ever 
regularly chewing nass showed increased ESCC risk, with an 
adjusted OR (95% CI) of 1.99 (1.21 –3.28). Average intensity of use 
(P for trend ¼ 0.004), duration of use (P for trend ¼ 0.02), 
cumulative use (P for trend ¼ 0.007), and age of first use (P for 
trend ¼ 0.01), all showed significant associations with risk 
(Table 3). 
Adjusted ORs (95% CIs) for cigarette use alone, hookah use 
alone, nass chewing alone, and combinations of two or more types 
were 1.50 (0.92 –2.43), 1.69 (0.76 –3.77), 2.91 (1.46 – 5.77), and 2.11 
(1.15–3.86), respectively (Table 4). Compared with using neither 
(Table 4), tobacco use alone, opium use alone, and a combination 
of the two were all significantly associated with higher ESCC risk, 
with adjusted ORs (95% CIs) of 1.70 (1.05 –2.73), 2.12 (1.21 – 3.74), 
and 2.35 (1.50 –3.67), respectively. Using results from Table 4, 
tobacco and opium use accounted for 30% of the cases in this 
study. 
Only 21 subjects, 7 cases (2%) and 14 controls (2%), had ever 
used alcohol for 6 months or more, adjusted OR (95% CI) 0.93 
(0.37–2.34). There was no significant association between 
intensity, duration, cumulative use, or age of first use of alcohol 
with ESCC risk (data not shown). 
DISCUSSION 
Our study showed that opium consumption, tobacco smoking, and 
chewing, but not alcohol consumption, are associated with higher risk 
of ESCC in Golestan Province. The area is well-placed to study the 
relationship between opium use and ESCC, both of which are 
common. A large proportion of the world’s opium is produced in 
Afghanistan, which borders Iran, and it is still commonly used in this 
region as a traditional treatment of pain, diarrhoea, and insomnia. An 
ecologic study in northern Iran found that 50% (20 out of 40) of 
adults in ESCC high-risk areas, compared with only 11% (10 out of 
90) of those in medium- or low-risk areas, tested positive for urine 
morphine metabolites (Joint Iran –IARC Study Group, 1977). In a 
subsequent study of 1590 rural individuals, the prevalence of 
appreciable levels (X1 mg ml  -1) of urinary morphine metabolites 
was almost six-fold higher among residents of high-risk vs low-risk 
areas (Ghadirian et al, 1985). Among the spouses of 41 cases and 41 
age-matched controls, there was a two-fold, nonsignificant, increased 
risk associated with the presence of urinary morphine metabolites. 
Previous studies in Iran (Cook-Mozaffari et al, 1979; Ghadirian 
et al, 1985) avoided using questionnaires to ask about opium use, 
partly because it can be a sensitive subject in many populations, 
which may limit the validity of questionnaire responses. This was 
tested during the pilot phase of an ongoing cohort study 
in Golestan by interviewing subjects twice and collecting urine 
samples twice, 2 months apart (Abnet et al, 2004). Overall 
agreement between the responses in the two interviews for ever 
using opium was excellent and above 0.99, the corresponding 
k-statistic being 0.96 (Abnet et al, 2004). The validity of self-
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reported current opium use was also high. Using the presence of 
codeine or morphine in the urine, self-report had a sensitivity of 
0.93 and specificity of 0.89 (Abnet et al, 2004), so we accepted 
questionnaire to document opium use. The results of our study 
showed a two-fold increased risk of ESCC associated with opium 
use. People in Golestan may start using opiates to alleviate pain 
prior to their cancer diagnosis and, therefore, reverse causality is a 
concern. However, excluding the cases and controls who had 
recently started using opium from the analysis made no material 
difference in the study results, and younger age at first use was a 
strong predictor of cancer risk. Limiting the analysis to tobacco 
nonusers, the results remained essentially unchanged. The 
percentage of opium users in ESCC case subjects (30%) found in 
this study is close to the percentage (33%) found in the pilot phase 
study (Islami et al, 2004). 
The two forms of opium used by the subjects of this study were 
teriak (crude opium) and shireh (refined opium). Shireh is usually 
made by boiling teriak (or a mixture of teriak and opium pyrolysates 
obtained after smoking opium) with water, filtering the mixture 
several times, and, then, evaporating the filtrate until a gummy 
consistency is achieved. Both teriak and shireh can be smoked or 
ingested. We found that consumption of both teriak and shireh are 
common, and both are associated with increased risk of ESCC, also 
both, smoking and ingesting, alone or in combination. 
Neither teriak nor shireh themselves were mutagenic in the 
Ames test (Hewer et al, 1978). However, either smoking or inhaling 
the smoke involves exposure to potential carcinogens, including 
polycyclic aromatic hydrocarbons (PAHs) to which industrial 
exposure may cause cancers of the lung, bladder, and skin 
(Denissenko et al, 1996; Boffetta et al, 1997; Hecht, 2003). Smoke 
condensates from opium and morphine cause mutations in 
Salmonella typhimurium (Hewer et al, 1978; Malaveille et al, 
1982), sister chromatid exchanges in human lymphocytes (Perry 
et al, 1983), and morphological transformations in cultured Syrian 
hamster embryo cells (Friesen et al, 1985), whereas crude opium 
itself is not a mutagen (Hewer et al, 1978; Malaveille et al, 1982). 
The mechanisms responsible for the carcinogenic effects of opium 
and shireh need investigation. 
In Western countries, cigarette smoking increases ESCC risk by 
approximately 3 – 5-fold (Tuyns, 1983; Brown et al, 1994, 2001). 
However, in some high-risk areas, such as Linxian (China), 
smoking plays a much less significant role in the aetiology of 
ESCC, and the relative risk for ever-cigarette smoking is only 1.3 
(Tran et al, 2005). The case – control study conducted by IARC and 
IPHR in the 1970s in Golestan Province showed an almost two-fold 
risk of ESCC associated with tobacco smoking (Cook-Mozaffari 
et al, 1979) and adjusted OR of 1.47 confirms a weak-to-moderate 
association in Golestan. Discordance between smoking prevalence 
and ESCC rates in women and men in these high risk areas, is in 
agreement with the finding of smoking is not a strong risk factor in 
these population. In Linxian, o1% of women and approximately 
70% of men smoke (Abnet et al, 2001), yet ESCC rates are nearly 
equal in the two sexes as in Golestan, where the prevalence of ever 
smoking ranges from 1% in rural women to 39% in urban men 
(Pourshams et al, 2004), suggesting that most ESCC cases in 
Linxian and Golestan are due to other factors. This relatively weak 
association between smoking and ESCC risk may also be due in 
part to the relatively low cumulative tobacco exposure; median 
cumulative use among smoking controls in this study was only 
13.5 pack-years. 
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